National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
Bronwen E ShawAntonio Martin Jimenez-JimenezLinda J BurnsBrent R LoganFarhad KhimaniBrian C ShafferNirav N ShahAlisha MussetterXiao-Ying TangJohn M McCartyAsif AlaviNosha FarhadfarKatarzyna JamiesonNancy M HardyHannah ChoeRichard F AmbinderClaudio AnasettiMiguel-Ángel PeralesStephen R SpellmanAlan HowardKrishna V KomanduriLeo LuznikMaxim NorkinJoseph A PidalaVoravit RatanatharathornDennis L ConferSteven M DevineMary M HorowitzJavier Bolaños-MeadePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Our prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.